Colestipol: A Review of its Pharmacological Properties and Therapeutic Efficacy in Patients with Hypercholesterolaemia

Drugs

Volumn 19, Issue 3, 1980, Pages 161-180

  Heel, R C ^a   Brogden, R N ^a   Pakes, G E ^a   Speight, T M ^a   Avery, G S ^a  

^a Australasian Drug Information Services ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTIPOL; COLESTYRAMINE; DIGITALIS GLYCOSIDE; THIAZIDE DIURETIC AGENT;

ADVERSE DRUG REACTION; CONSTIPATION; DIGESTIVE SYSTEM; DRUG INTERACTION; DRUG THERAPY; GALLSTONE; GASTROINTESTINAL SYMPTOM; HYPERCHOLESTEROLEMIA; INTOXICATION; LARGE INTESTINE; LIVER TOXICITY; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PROTHROMBIN TIME; REVIEW; THERAPY;

COLESTIPOL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERCHOLESTEROLEMIA; KINETICS; POLYAMINES; PROTEIN BINDING;

DIGITALIS;

EID: 0019222584     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198019030-00001     Document Type: Article

References (88)

1. Long-term effect of colestipol on serum cholesterol and triglycerides in humans
2. Effets sur les lipides sériques, d’un traitement prolongé (16 mois) au colestipol (u. 26597A) dans l’hyperlipoprotéinémie familiale de type II
3. Effect of digitalis-binding resins on cardiac glycoside plasma levels
4. Digitalis intoxication. Treatment with a new steroid-binding resin
5. Effect of Colestid on serum lipids of patients with type IV hyperlipoproteinemias
6. Trattamento a lungo termine dell’ipercolesterolemia familiare con colestipol, una nuova resina a scambio anionico
7. Changes in plasma lipoprotein lipids in hypercholesterolaemic patients treated with the bile acid-sequestering resin, colestipol
8. Increased plasma cholesterol esterifying activity during colestipol resin therapy in man
9. Colestipol hydrochloride, a new hypolipidemic drug: A two-year study
10. The effect of colestipol hydrochloride or cholestyramine on the bioavailability and pharmacokinetics of Clofibrate
11. Cholesterol hydrochloride in hyper-cholesterolemic patients — effect on serum cholesterol and mortality
12. Colestipol and Clofibrate in hypercholesterolemia
13. Les effets du colestipol associé au Clofibrate sur les lipides seriques dans l’hyperlipoprotéinémie familiale de type II
14. Long-term trial with colestipol plus Clofibrate in familial hypercholesterolaemia
15. Long-term effects of colestipol (U-26, 597A) on plasma lipids in familial type II hyperbetalipoproteinaemia
16. Anion-exchange resins in pseudomembranous colitis
17. Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemia
18. Pediatric familial type II hyperlipoproteinemia: Therapy with diet and colestipol resin
19. The effects of colestipol resin and of colestipol plus Clofibrate on the turnover of plasma cholesterol in man
20. Long-term cholesterol-lowering effect on colestipol resin in humans
21. Colestipol, Clofibrate, and phytosterols in combined therapy of hyperlipidaemia
22. The effects of a new bile acid-sequestrant, colestipol (U-26, 597A), on serum cholesterol in a hyperlipidemic prison population
23. Cholesterol-lowering effect of colestipol hydrochloride given twice daily in hypercholesterolemic patients
24. Etude d’un traitement mixte de colestipol et de β-sitosterol dans l’hypercholestérolémie
25. Effect of colestipol, a new bile acid sequestrant, on the absorption of phenprocoumon in man
26. Colestipol in familial type II hyperlipoproteinemia: A three-year trial
27. Enhancement of cholesterol turnover in rats by a catatoxic steroid (PCN) and a bile acid sequestrant (colestipol-HCl)
28. Effect of cholestyramine and colestipol on the absorption of methyldopa and hydrochlorothiazide
29. Effect of bile acid sequestering agents on the absorption of aspirin, tolbutamide and warfarin
30. Effects of Clofibrate and colestipol on lipoprotein levels in type IIa hyperlipoproteinemia
31. Heterozygous familial hypercholesterolaemia: Treatment with combined drug regimens
32. Effect of colestipol on gastrointestinal absorption of chlorothiazide in man
33. In vitro binding of drugs to colestipol hydrochloride
34. Binding of bile salts vitro by nonnutritive fiber
35. In Vitro binding of bile acids and bile salts
36. Effect on colestipol (U-26, 597A) on experimental atherosclerosis in rabbits (36984)
37. Use of combined diet and colestipol in long-term (7–7½ years) treatment of patients with type II hyperlipoproteinemia
38. On the interpretation and potential diagnostic value of measurements related to lecithin: cholesterol acyltransferase activity
39. Results of colestipol therapy in type II hyperlipoproteinemia
40. In vitro binding of various biological substances by two hypocholesterolaemic resins
41. The effect of hypolipidemic drugs on plasma lipoproteins
42. Lipid-lowering drugs and hyperlipidaemia
43. Dietary and drug treatment of primary hyperlipoproteinaemia
44. Changes in cholesterol metabolism by colestipol hydrochlorine in hypercholesterolaemic patients
45. Differences among hyperlipoproteinaemic subjects in the response of lipoprotein lipids to resin therapy
46. Effects of colestipol, a new bile acid-sequestering resin, on cholesterol metabolism in man
47. Controlled clinical trial of a new bile acid-seqúestering resin, colestipol, in the treatment of hypercholesterolaemia
48. Long-term therapy of diet-resistant hypercholesterolemia with colestipol
49. Eine vergleichende Untersuchung von Colestyramin und Colestipol bei Kindern und Heranwachsenden mit familiarer Hypercholesterinamie
50. Ervaringen met een nieuw cholesterolemieverlagend hars colestipol (U-26, 597A, Upjohn)
51. Effects of colestipol and Clofibrate on cholesterol turnover
52. Treatment of hypercholesterolaemia with colestipol: A bile sequestrating agent
53. Effects of colestipol (U-26, 597A), a new bile acid sequestrant, on serum lipids in experimental animals and man
54. Effects of colestipol hydrochloride (U-26, 597A) on serum and fecal lipids in dogs
55. Comparison of cholesterol-reducing effects of cholestyramine and a new sequestrant of bile acids (colestipol)
56. Drug absorption in gastrointestinal disease with particular reference to malabsorption syndromes
57. Effects of colestipol hydrochloride and neomycin sulfate on cholesterol turnover in the rat
58. Effects of colestipol hydrochloride and neomycin sulfate on cholesterol turnover in the rat
59. Effects of colestipol hydrochloride on drug absorption in the rat II
60. Effects of colestipol hydrochloride on drug absorption in the rat I: Aspirin, l-thyroxine, phenobarbital, cortisone, and sulfadiazine
61. Effects of colestipol hydrochloride, Clofibrate, and probucol in normocholesterolemic rats
62. Combined effect of colestipol and Clofibrate on plasma lipids and lipoprotein levels in type IIa hyperlipoproteinemia
63. Lee, G.; Campion, B. and Hunninghake, D.B.: Colestipol, an investigational bile-acid sequestering agent for lowering serum cholesterol
64. Clofibrate-induced low density lipoprotein elevation. Therapeutic implications and treatment by colestipol resin
65. Effect of a bile acid sequestrant, colestipol, on serum cholesterol, fecal bile acids and neutral sterols in human subjects
66. Colestipol hydrochloride for treatment of hypercholesterolemia in a family practice: Five year study
67. The effect of colestipol or cholestyramine on serum cholesterol and triglycerides in a long-term controlled study
68. Long-term treatment of hypercholesterolemia with colestipol hydrochloride
69. Colestipol may be well tolerated for up to eight years
70. Response of hyperlipoproteinemia to colestipol
71. Colestipol therapy of hyperlipidemia in man (38419)
72. Effect of colestipol on fecal excretion of cholate in man
73. Colestipol, Clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia
74. Management of hyperlipidemia. Diet and drugs
75. Cholesterol, colestipol and coronary heart disease
76. Effect of a new bile sequestering resin (U-26957A) on lipoprotein concentrations in type II hyperlipoproteinemia
77. Preparation of (l4C) colestipol hydrochloride and its disposition in the human, dog and rat
78. Plasma 25-hydroxy-vitamin D in familial hypercholesterolemic children receiving cholestipol resin
79. Effect of cholestyramine and colestipol on the absorption of Phenytoin
80. The effect of colestipol on digitoxin plasma levels
81. Toxicologic, reproductive and teratologic, reproductive and teratologic studies of colestipol hydrochloride, a new bile acid sequestrant
82. The effects of colestipol on the metabolism of very-low-density lipoproteins in man
83. Effects of a steroid binding resin on serum glycoside levels in experimental animals
84. Drug treatment of hyperlipidemia